Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Heron Therapeutics
HRTX
Heron Therapeutics
Concentrated Revenues Will Hinder Biotech Prospects With Some Resilience
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
25 Aug 25
Updated
25 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$3.00
53.0% undervalued
intrinsic discount
25 Aug
US$1.41
1Y
-26.9%
7D
9.3%
Loading
1Y
-26.9%
7D
9.3%
Author's Valuation
US$3.0
53.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$3.0
53.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-228m
216m
2014
2017
2020
2023
2025
2026
2028
Revenue US$216.3m
Earnings US$41.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.96%
Biotech revenue growth rate
11.91%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.99%
Calculation
US$41.15m
Earnings '28
x
14.32x
PE Ratio '28
=
US$589.05m
Market Cap '28
US$589.05m
Market Cap '28
/
156.94m
No. shares '28
=
US$3.75
Share Price '28
US$3.75
Share Price '28
Discounted to 2025 @ 7.97% p.a.
=
US$2.98
Fair Value '25
